Monogram Orthopedics’ Shares Trade Publicly on NASDAQ for First Time

Monogram Orthopedics, a developer of patient-optimized, 3D-printed orthopedic implants enabled by robotics with advanced pre-operative imaging, has raised $17,216,147. Also, its common stock began trading on the NASDAQ May 18, 2023 under the ticker symbol “MGRM.”
 
Monogram Orthopedics is working to develop a product solution architecture with the long-term goal of enabling patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging.
 
The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
 
It has not yet made 510(k) premarket notification submissions or obtained 510(k) clearances for any of its robotic products.
 
Digital Offering, LLC, acted as the lead managing selling agent, along with R.F. Lafferty as syndicate manager for the offering. Cambria Capital, LLC, DealMaker Securities, and OpenDeal Broker LLC participated as selling group members. CrowdCheck Law LLP acted as counsel to Monogram Orthopaedics, and Bevilacqua PLLC acted as counsel for the managing selling agent.